Study on Integrating the Systematic Detection of Breast Arterial Calcifications (BAC) in Routine Mammograms Within a Population-based Breast Cancer Screening Programme to Improve Cardiovascular Prevention in Women. (DUALMAMO)

November 10, 2026 updated by: Helena Tizón Marcos, Hospital del Mar Research Institute (IMIM)

Heart disease is the leading cause of death in women, yet it often goes undetected until it's too late. This project uses a simple clue found during routine breast cancer screenings-breast arterial calcification (BAC)-to spot early signs of heart risk in women aged 50 to 70. Those identified with BAC will be invited to take part in a personalized prevention program. This includes support to adopt healthier habits-like being more active, eating better, sleeping well, and managing stress-and regular checks of key health measures such as blood pressure and cholesterol. The study will compare two levels of care: a nurse-led program and a more intensive, app-supported version.

By turning mammograms into a dual-purpose tool for breast and heart health, this project empowers women with early action to reduce risk and improve long-term well-being.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background and rationale Cardiovascular disease (CVD) is a leading cause of death in women, and cardiovascular risk is frequently underrecognized in this population. Breast arterial calcification (BAC), a form of medial vascular calcification visible on mammography, has been associated with increased cardiovascular risk. Because mammography is already performed in population-based breast cancer screening, BAC offers an opportunity to identify women who may benefit from cardiovascular prevention without additional imaging or radiation exposure. Artificial intelligence (AI) algorithms enable automated, scalable BAC detection within screening workflows.

Study design DUALMAMO combines two components: (1) AI-based detection of BAC in screening mammograms from Hostpital del Mar breast cancer screening program, and (2) a randomized controlled trial among eligible BAC-positive women, comparing a digital multicomponent lifestyle intervention with standard primary care advice. The study assesses whether this strategy improves cardiovascular risk factor control and, over longer follow-up, reduces major adverse cardiovascular events. Outcomes are detailed in the Outcome Measures section.

Procedures Women are eligible once their screening result is known. BAC-positive women are identified by the AI algorithm and invited by letter to participate through the study app/web platform. After informed consent, participants attend a baseline in-person visit (questionnaires, blood test, and clinical measurements) and are randomized through the app. A second in-person visit takes place at 6 months, with the blood test repeated if no recent result is available. Clinical events are followed up to 36 months through.

Implementation The trial also evaluates recruitment, retention, adherence, and cost-effectiveness to inform the potential integration of BAC-based cardiovascular risk identification into routine breast cancer screening.

Study Type

Interventional

Enrollment (Estimated)

400

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Women participating in the population-based mammography screening program in the Hospital del Mar.
  • Presence of breast arterial calcification (BAC+) on the screening mammogram, as detected by the AI algorithm, ang confirmed by the Radiologists
  • Access to an internet-connected device and ability to use the study app/web platform.
  • Signed informed consent.

Exclusion Criteria:

  • Breast cancer diagnosis or recall for additional testing following the screening mammogram.
  • History of stroke, myocardial infarction, or angina pectoris.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group

A blood test to determine the following:

-Colesterol total (mg/dL)

  • Colesterol LDL (mg/dL)
  • Colesterol HDL (mg/dL)
  • Triglicéridos (mg/dL)
  • Glucosa en ayunas (mg/dL)
  • Hemoglobina glicosilada (HbA1c, %)
  • Lp(a)

Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ)

Participants receive 6 months of access to a digital platform with structured educational modules on cardiovascular risk factors (sleep, diet, cholesterol, glucose, weight, physical activity, blood pressure, smoking and environmental factors), together with a personalized physical activity program. Participants also receive their baseline laboratory results review and the same information leaflet on breast arterial calcification (BAC) provided to the usual care arm. Allocation is by random assignment through the study application.

Active Comparator: Control Group

A blood test to determine the following:

-Colesterol total (mg/dL)

  • Colesterol LDL (mg/dL)
  • Colesterol HDL (mg/dL)
  • Triglicéridos (mg/dL)
  • Glucosa en ayunas (mg/dL)
  • Hemoglobina glicosilada (HbA1c, %)
  • Lp(a)

Cardiovascular risk factors questionnaire Patient Health Questionnaire-9 (PHQ-9) EuroQol 5-Dimension (EQ-5D) Chrononutrition Profile - Questionnaire (CP-Q) International Physical Activity Questionnaire (IPAQ)

Participants receive personalized cardiovascular health advice reflecting routine primary care practice, together with written information on BAC and its cardiovascular significance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of participants achieving cardiovascular risk control targets
Time Frame: 6 months

LDL cholesterol <100 mg/dL, blood pressure <140/90 mmHg, and/or ≥20% reduction in cardiovascular risk

6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in depressive symptoms
Time Frame: 6 months

PHQ-9

6 months
Change in health-related quality of life
Time Frame: 6 months

EuroQol-5 (EQ-5D)

6 months
Change in physical activity
Time Frame: 6 months

IPAQ

6 months
Change in crononutrition profile
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2028

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 2025/12505/I
  • 2025 (U.S. NIH Grant/Contract)
  • PI25/00050 (Other Grant/Funding Number: ISCIII)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.